EUVIMEDEUVIMED entdecken
Open Access

Feasibility of MRI ‐Guided Transperineal Implantation of Microdevices for Drug Delivery and Response Assessment in Prostate Cancer

Quinn Rainer iD, Kemal Tuncali, Wooseok Ahn, Fanni Viktoria Santa, Michelle Hirsch, Sharath Bhagavatula, Fumitaro Masaki, Clarissa Therese Young, Courtney Marlin, Samantha Martin, Destiny U Matthew, Filipe De Carvalho und 6 weitere

Journal of Magnetic Resonance Imaging · 2025

DOI: 10.1002/jmri.29784 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Magnetic Resonance Imaging, 2025. Verfasst von Quinn Rainer und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Magnetic Resonance Imaging, Drug Delivery Systems, Magnetic Resonance Imaging, Interventional. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NIBIB NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate cancer (PCa) treatment often involves systemic therapies with varying mechanisms of action, affecting individuals differently. Implantable microdevices (IMDs) are designed to test multiple drugs within a patient's tumor, but the feasibility of MRI‐guided placement in PCa has not been evaluated.

Purpose

To provide proof of concept for placing IMDs into lesions with MRI guidance to predict patient‐specific responses to therapies. Study Type Prospective. Population Fifteen participants undergoing prostatectomy for PCa. Field Strength/Sequence 3T MRI With T2‐weighted (T2W). Assessment In‐bore MRI‐targeted placement of IMDs was performed. Intra‐procedural MRI scans were reviewed by a radiologist, using needle artifacts on T2W images to guide IMD placement. A genitourinary pathologist performed Gleason scoring around the IMDs. Drug response analysis included Enzalutamide + Nivolumab, Enzalutamide + Docetaxel, and single‐agent Enzalutamide. Statistical Tests Mann–Whitney U test for continuous variables, p < 0.05 for significance.

Results

Of 53 IMDs implanted into suspicious lesions in 14 participants, 48 (90%) were successfully placed within the lesions. The average distance from the needle tip to the tumor was 8.32 ± 4.02 mm. Larger lesion size ( p = 0.009) and lower prostate imaging‐reporting and data system score ( p = 0.031) were significantly associated with successful IMD placement. Of the 53 IMDs, 49 (92.4%) were retrieved for histopathology and drug response analysis. In four participants, Gleason scores around the device were lower than preplacement biopsy in two and equal in two. Additionally, drug analysis in one patient demonstrated the feasibility of drug response analysis, revealing differences in apoptotic index, lymphocyte infiltration, dysplastic cell composition, and cellular profiles for each treatment. No complications or adverse events occurred.

Conclusion

IMDs can be effectively and safely placed in prostate lesions using MRI guidance, with feasible histological and drug response analyses. Evidence Level : 2. Technical Efficacy : Stage 1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMagnetic Resonance ImagingDrug Delivery SystemsMagnetic Resonance Imaging, InterventionalHumansMaleFeasibility StudiesProspective StudiesAgedMiddle AgedProstatectomyProstateTreatment OutcomeNitriles

Stichwörter der Autor:innen

MRIinterventional radiologymicrodeviceprostate cancer

Substanzen

Nitriles

Autor:innen und Institutionen

  • Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Canon Medical Research USA Inc, Cambridge, Massachusetts, USA.
  • Department of Urology, Brigham and Women's Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Quinn Rainer, Nobuhiko Hata

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NIBIB NIH HHS
  • National Institutes of Health

Zitieren

APA

Rainer, Q., Tuncali, K., Ahn, W., Santa, F. V., Hirsch, M., Bhagavatula, S., Masaki, F., Young, C. T., Marlin, C., Martin, S., Matthew, D. U., De Carvalho, F., Dominas, C. A., Stone, B. V., Tempany, C., Jonas, O., Kibel, A. S., & Hata, N. (2025). Feasibility of MRI ‐Guided Transperineal Implantation of Microdevices for Drug Delivery and Response Assessment in Prostate Cancer. Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.29784

Vancouver

Rainer Q, Tuncali K, Ahn W, Santa FV, Hirsch M, Bhagavatula S, et al. Feasibility of MRI ‐Guided Transperineal Implantation of Microdevices for Drug Delivery and Response Assessment in Prostate Cancer. Journal of Magnetic Resonance Imaging. 2025. doi:10.1002/jmri.29784

BibTeX
@article{Rainer2025,
  author = {Rainer, Quinn and Tuncali, Kemal and Ahn, Wooseok and Santa, Fanni Viktoria and Hirsch, Michelle and Bhagavatula, Sharath and Masaki, Fumitaro and Young, Clarissa Therese and Marlin, Courtney and Martin, Samantha and Matthew, Destiny U and De Carvalho, Filipe and Dominas, Christine A and Stone, Benjamin V and Tempany, Clare and Jonas, Oliver and Kibel, Adam Stuart and Hata, Nobuhiko},
  title = {Feasibility of MRI ‐Guided Transperineal Implantation of Microdevices for Drug Delivery and Response Assessment in Prostate Cancer},
  journal = {Journal of Magnetic Resonance Imaging},
  year = {2025},
  doi = {10.1002/jmri.29784}
}
Kostenlos starten →